Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AGIO
AGIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AGIO News
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
Apr 01 2026
Newsfilter
Health Care Stocks Rise 2% Boosting Market
Mar 31 2026
Yahoo Finance
Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat
Mar 31 2026
Fool
Agios Executive Sells Shares for Tax Obligation
Mar 31 2026
Fool
Agios Pharmaceuticals' Mitapivat Gains FDA Attention for Sickle Cell Treatment
Mar 31 2026
NASDAQ.COM
Agios Executive Sells Shares for Tax Payment
Mar 31 2026
NASDAQ.COM
Agios Pharmaceuticals Seeks Accelerated Approval for Pyrukynd Expansion
Mar 31 2026
seekingalpha
Agios Seeks Accelerated Approval for Mitapivat in Sickle Cell Disease
Mar 31 2026
Newsfilter
Agios Pharmaceuticals' PYRUKYND Approved in UAE for Thalassemia Treatment
Mar 02 2026
Yahoo Finance
Commodore Capital Fully Sells Agios Pharmaceuticals Shares
Feb 23 2026
Fool
Rock Springs Capital Reduces Agios Holdings
Feb 17 2026
Fool
Agios Pharmaceuticals Q4 2025 Earnings Call Insights
Feb 12 2026
seekingalpha
Agios Pharmaceuticals Reports Q4 2025 Earnings and FDA Approval
Feb 12 2026
seekingalpha
Agios Pharmaceuticals Reports Key 2025 Financial Highlights
Feb 12 2026
Newsfilter
Agios Pharmaceuticals to Announce Q4 Earnings on February 12
Feb 11 2026
seekingalpha
Key Earnings Reports and Economic Outlook This Week
Feb 08 2026
CNBC
Show More News
